Alan Fuhrman Purchases 9,500 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) CFO Alan Fuhrman acquired 9,500 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were bought at an average price of $16.00 per share, with a total value of $152,000.00. Following the completion of the purchase, the chief financial officer now directly owns 12,849 shares of the company’s stock, valued at approximately $205,584. This represents a 200.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tyra Biosciences Stock Performance

Shares of TYRA opened at $16.39 on Friday. The business’s fifty day moving average price is $22.39 and its two-hundred day moving average price is $19.88. The firm has a market capitalization of $865.56 million, a price-to-earnings ratio of -9.70 and a beta of 1.08. Tyra Biosciences, Inc. has a 52 week low of $10.60 and a 52 week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.09. As a group, research analysts forecast that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. RA Capital Management L.P. raised its stake in shares of Tyra Biosciences by 43.9% during the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after buying an additional 3,180,155 shares during the last quarter. BVF Inc. IL grew its holdings in Tyra Biosciences by 70.1% during the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after acquiring an additional 1,921,599 shares during the period. Perceptive Advisors LLC raised its position in shares of Tyra Biosciences by 50.5% during the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after acquiring an additional 338,208 shares during the last quarter. Ally Bridge Group NY LLC acquired a new position in shares of Tyra Biosciences in the 2nd quarter valued at $4,232,000. Finally, Ensign Peak Advisors Inc acquired a new position in shares of Tyra Biosciences in the 2nd quarter valued at $3,047,000. Institutional investors own 84.14% of the company’s stock.

Wall Street Analyst Weigh In

TYRA has been the subject of a number of recent analyst reports. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $22.00 to $31.00 in a research report on Friday, October 18th. Wedbush reiterated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research note on Friday, October 25th. Oppenheimer boosted their target price on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. HC Wainwright raised their price target on Tyra Biosciences from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, October 28th. Finally, Piper Sandler started coverage on Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $31.40.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.